Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

09 sept. 2024 08h00 HE | Source: Upstream Bio, Inc.

Upstream Bio Announces Oral Presentation of New Data from a Phase 1b Multiple Ascending Dose Trial of Verekitug (UPB-101) in Adults with Asthma at the European Respiratory Society Congress

Upstream gives oral presentation of clinical data for verekitug in patients with severe asthma at European Respiratory Society congress
22 mai 2024 11h15 HE | Source: Upstream Bio, Inc.

Upstream Bio Presents Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society International Conference

Positive results from a Phase 1 dose ranging study of verekitug (UPB-101) in asthma presented at ATS 2024
15 mai 2024 07h00 HE | Source: Upstream Bio, Inc.

Upstream Bio to Present Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society (ATS) International Conference

Upstream Bio will present clinical data from dose-ranging study of verekitug (UPB-101) in adults with asthma at the American Thoracic Society conference